{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:04Z","timestamp":1790732944011,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with tuberculosis (TB) disease treated with multi\u2010drug regimens are at risk of developing drug induced liver injury (DILI), and DILI risk might be even higher in patients with underlying liver disease. We aimed to evaluate whether underlying chronic hepatitis B virus (HBV) and TB co\u2010infection are associated with a higher risk of TB therapy\u2010related DILI. We conducted a systematic review and meta\u2010analysis using MEDLINE\/PubMed from inception to 31 December 2021. Primary outcome assessed was development of DILI following multi\u2010drug TB treatment. Meta\u2010analysis using random\u2010effects models were utilized to evaluate whether underlying chronic HBV was associated with increased risk of DILI in patients undergoing active TB treatment. A total of 10 studies met inclusion criteria to be analysed, among which 520 patients had HBV\u2010TB co\u2010infection and 2988 patients had active TB disease without HBV. Prevalence of DILI was 21.9% in HBV\u2010TB co\u2010infected patients and 11.9% in TB patients without HBV. On meta\u2010analysis, HBV\u2010TB co\u2010infected patients had significantly higher risk of DILI when treated with TB therapies compared with TB patients without HBV (pooled risk ratio 1.98, 95% CI 1.38\u20132.83, I<jats:sup>2<\/jats:sup>\u00a0=\u200968%). Sub\u2010analysis of prospective cohort studies conducted after year 2000 detected a pooled risk ratio of 2.75 (95% CI 2.10\u20133.59, I<jats:sup>2<\/jats:sup>\u00a0=\u20090%). In conclusion, HBV\u2010TB co\u2010infected patients undergoing multi\u2010drug TB therapy have 2\u20133 times higher risk of DILI compared with TB patients without HBV. Routine HBV screening prior to initiation of TB therapy is critical for early identification of HBV\u2010TB co\u2010infection, so that clinicians can modify TB and HBV treatment and management to reduce risks of DILI.<\/jats:p>","DOI":"10.1111\/jvh.13751","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T04:24:10Z","timestamp":1663907050000},"page":"1107-1114","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Risk of drug\u2010induced liver injury in chronic hepatitis B and tuberculosis co\u2010infection: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"29","author":[{"given":"Christina","family":"Chou","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology Highland Hospital, Alameda Health System  Oakland California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolette","family":"Veracruz","sequence":"additional","affiliation":[{"name":"School of Medicine Central Michigan University  Mt Pleasant Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit S.","family":"Chitnis","sequence":"additional","affiliation":[{"name":"Tuberculosis Section, Division of Communicable Disease Control and Prevention Alameda County Public Health Department  San Leandro California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8923-2806","authenticated-orcid":false,"given":"Robert J.","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Stanford University School of Medicine  Stanford California USA"},{"name":"Gastroenterology and Hepatology Section Veterans Affairs Palo Alto Healthcare System  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Tuberculosis (TB)","author":"World Health Organization","year":"2021"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140881"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10903-021-01231-6"},{"key":"e_1_2_9_5_1","volume-title":"Hepatitis B","author":"World Health Organization","year":"2021"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001533"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3192-8"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcma.2015.12.006"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3988"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-013-9535-8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083892"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0377-1237(06)80155-3"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i16.2518"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0012-3692(15)34481-0"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310129"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1997.tb00353.x"},{"issue":"5","key":"e_1_2_9_20_1","first-page":"616","article-title":"Hepatitis C virus infection increases hepatitis risk during anti\u2010tuberculosis treatment","volume":"14","author":"Chien JY","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2020.1788223"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820002861"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05704.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2011.04.005"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"issue":"4","key":"e_1_2_9_27_1","first-page":"660","article-title":"Antiviral therapy for hepatitis B prevents liver injury in patients with tuberculosis and hepatitis B coinfection","volume":"70","author":"Lui GCY","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"e_1_2_9_28_1","first-page":"1667","article-title":"Clinical effect of lamivudine in treating liver function lesion caused by hepatitis B combined with anti\u2010TB drugs","volume":"31","author":"Han Y","year":"2018","journal-title":"Pak J Pharm Sci"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13751","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T03:01:10Z","timestamp":1692586870000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/jvh.13751"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13751","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"2021-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}